While mutations in the KRAS protein are known to ... high risk of their precancerous lesions progressing to PDAC. While FGFR inhibitors are clinically available, Tonelli cautioned that their ...

However, epithelial cancers — such as bladder cancer — also exhibit deregulation and mutation of FGFR3 ... R3Mab reduced the phosphorylation of FGFR substrate 2α and mitogen-activated ...

These mutations are particularly common in the luminal ... in people with advanced urothelial cancer and FGFR alterations whose condition had progressed on or after one or two prior treatments ...

Cogent Biosciences (COGT) announced preclinical data from four pipeline programs during poster sessions at the American Association for Cancer ...

Title: The Reversible and Selective FGFR2/3 inhibitor CGT4859 has superior target coverage of resistance mutations missed by leading FGFR inhibitors FGFR inhibitors are well-established oncogenic ...